TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00098306
Drug: Optimized Background Therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Maraviroc was given either once or twice per day with the dose adjusted according to the optimized background therapy
Study: NCT02183116
Drug: Meloxicam
Normalized name: Meloxicam
DrugBank: Meloxicam (DB00814)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT03803553
Drug: FOLFIRI Protocol
Normalized name: Olay Professional Acne Protocol
Approvals — FDA: no, EMA: no, PMDA: no
Description: FOLFIRI cycle will be two weeks (14 days) long, with FOLFIRI administered on Days 1-3. Participants will receive up to 12 two-week cycles (for a total of 24 weeks) of FOLFIRI chemotherapy.
Study: NCT01074697
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saline water
Study: NCT01026714
Drug: flurbiprofen
Normalized name: Flurbiprofen
DrugBank: Flurbiprofen (DB00712)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: assessment of flurbiprofen plasmatic and capillary rates
Study: NCT01026714
Drug: flurbiprofen, rifampicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: assessment of flurbiprofen plasmatic and capillary rates
Study: NCT01187407
Drug: LY2216684
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01187407
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01026714
Drug: flurbiprofen + fluconazole
Normalized name: Flurbiprofen
DrugBank: Flurbiprofen (DB00712)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: assessment of flurbiprofen plasmatic and capillary rates
Study: NCT01710917
Drug: Targinact® (oxycodon/naloxon)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01332097
Drug: BCT197
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01332097
Drug: BCT197 placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: capsules
Study: NCT00098306
Drug: Optimized Background Therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients will be randomly (2:2:1) assigned to one of three groups: Optimized Background Therapy \[OBT (3-6 drugs based on treatment history and resistance testing)\] + maraviroc (UK-427,857) 150 mg taken once daily, OBT + maraviroc (UK-427,857) 150 mg taken twice daily, or OBT alone.
Study: NCT00098306
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients will be randomly (2:2:1) assigned to one of three groups: Optimized Background Therapy \[OBT (3-6 drugs based on treatment history and resistance testing)\] + maraviroc (UK-427,857) 150 mg taken once daily, OBT + maraviroc (UK-427,857) 150 mg taken twice daily, or OBT alone.
Study: NCT02191280
Drug: Antistax®, high dose
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02191280
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00098306
Drug: Optimized Background Therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients will be randomly (2:2:1) assigned to one of three groups: Optimized Background Therapy \[OBT (3-6 drugs based on treatment history and resistance testing)\] + maraviroc (UK-427,857) 150 mg taken once daily, OBT + maraviroc (UK-427,857) 150 mg taken twice daily, or OBT alone. The study will enroll over approximately a 9 month period with 48 weeks of treatment.
Study: NCT03269695
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: SC QW
Study: NCT02715492
Drug: LMWH
Normalized name: Low-molecular-weight heparin
Approvals — FDA: no, EMA: no, PMDA: no
Description: (Enoxheparin) 1 IU/kg per dose twice daily for 2 weeks from the 1st day of TACE
Study: NCT01854489
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: The volunteers will be given Oral placebo at 20.00 for 7 days \[Phase 1 \]
Study: NCT00084734
Drug: capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Oral
Study: NCT00099723
Drug: VSL#3
Normalized name: VSL#3
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02307513
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablets for oral administration
Study: NCT02004106
Drug: RO6895882
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive RO6895882 at different dose levels and schedules defined in respective arms as IV infusion.
Study: NCT03233347
Drug: Doxorubicin
Normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given IV
Study: NCT01209221
Drug: Placebo - MAD
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once or twice daily doses of matching placebo to RO5271983 for 14 days
Study: NCT02726477
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients will be administrated with placebo powder at a dosage of 1g/kg twice a day after randomisation.
Study: NCT01209221
Drug: Placebo - SAD
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose of matching placebo to RO5271983 for up to 3 periods
Study: NCT01209221
Drug: RO5271983 - MAD
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Once or twice daily doses of RO5271983 for 14 days
Study: NCT00720174
Drug: Doxorubicin Hydrochloride
Normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given IV
Study: NCT01374178
Drug: LY2963016
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered subcutaneously
Study: NCT02827942
Drug: Clarithromycin 200 mg bid
Normalized name: Clarithromycin
DrugBank: Clarithromycin (DB01211)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Clarithromycin is antibiotics. It is involved in the standard first line regimen in Japan. Then, 200 mg of clarithromycin is dosed twice daily for 1 week.
Study: NCT01003639
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects will begin with four tablets daily. Tablets will be divided among two doses, taken with meals. Beginning on day 7, subjects will increase the dose by 1 pill every week until 16 tablets daily is reached (4 grams acetazolamide or placebo) or side effects prohibit increasing the dosage further. Thus, subjects who are able to tolerate the study medication will reach the maximum dose by day 84.
Study: NCT00839332
Drug: LY2603618
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01544504
Drug: Norepinephrine
Normalized name: Norepinephrine
DrugBank: Norepinephrine (DB00368)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Approximately 4.65 mL of a norepinephrine solution (400 mM, 82.3 mg/mL) will be applied topically to the study drug application site prior to each radiotherapy treatment (approximately 25-28 treatments).
Study: NCT00621816
Drug: placebo infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: blinded placebo infusion, to be infused at same rate as open-label nitroprusside infusion
Study: NCT02384655
Drug: Fenugreek seed meal
Normalized name: fenugreek seed meal
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3x3 capsules of fenugreek seeds per day for 14 days
Study: NCT00840671
Drug: 0.9% Saline Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.9% Saline Solution, 30 ml/day as intravenous infusion, first infusion after completion of thrombolytic therapy. Daily infusion for 10 consecutive days.
Study: NCT01324700
Drug: High severity group: Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants within high severity group were stratified to receive placebo (inactive ingredient matching the active medication in appearance).
Study: NCT01324700
Drug: Low severity group: Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants within low severity group were stratified to receive placebo (inactive ingredient matching the active medication in appearance).
Study: NCT03317223
Drug: CJ-12420/Clarithromycin/Amoxicillin
Approvals — FDA: no, EMA: no, PMDA: no
Description: CJ-12420 or Lansoprazole +Clarithromycin/Amoxicillin will be administrated twice a day, for 7 days
Study: NCT00130728
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: intravenous infusion of placebo at a dose of 15 mg/kg on the first day of each 3-week cycle
Study: NCT02456675
Drug: INCB040093
Approvals — FDA: no, EMA: no, PMDA: no
Description: INCB040093 sustained release (SR) tablets will be administered orally twice daily (BID) without regard to food.
Study: NCT02496143
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo will be supplied as Softgel capsules. The study will include up to four sequential dose cohorts. Two subjects in each cohort will be randomized to placebo and will receive 1, 2, 4 or 8 placebo capsules for Cohorts 1, 2, 3 or 4, respectively.
Study: NCT01187810
Drug: Methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Dose depends on subject age - for CNS positive patients, will be given in combination with cytarabine and hydrocortisone on days 8, 15, and 22 during course 1. For courses 2-6, will be administered intrathecally on day 8 for CNS negative ALL and NHL. For patients who are CNS positive, it will be given in combination with cytarabine and hydrocortisone on day 8 of courses 2-6.
Study: NCT03044587
Drug: Arm NaI-IRI + 5-FU + Leucovorin (Arm A)
Normalized name: 5-FU
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Nal-IRI (80 mg/m2 as a 1.5 hour infusion), 5-FU (2400 mg/m2 as 46 hour infusion) and Leucovorin (400 mg/m2 as 0.5 hour infusion) Cycle q2w
Study: NCT00003216
Drug: fluorouracil
Normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT02402946
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03515200
Drug: Doxorubicin
Normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given intravenously (IV).
Study: NCT01473472
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 tablets of placebo within 24 hours before first sexual relations, then 1 tablet of placebo every 24 hours during the period of sexual activity including the last sexual intercourse, finally, a last dose of 1 tablet of placebo approximatively 24 hours later
Study: NCT02483598
Drug: Buspirone and Grapefruit Juice
Normalized name: grapefruit juice
Approvals — FDA: no, EMA: no, PMDA: no
Description: Grapefruit juice will be given before and during buspirone administration to inhibit intestinal CYP3A4.
Study: NCT02970305
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo, taken as two tablets, once daily by mouth
Study: NCT00450398
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ex vivo flush of placebo control (200 mL Viaspan®) into the portal vein prior to transplant and 0.1 mL/kg placebo control (saline) IV to the transplant recipient prior to arterial reperfusion of the liver.
Study: NCT00099203
Drug: ibandronate [Bondronat]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6mg iv on days 1-3, and every 3-4 weeks
Study: NCT00099203
Drug: zoledronic acid
Normalized name: Zoledronic Acid
DrugBank: Zoledronic acid (DB00399)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 4mg iv on day 1 and every 3-4 weeks
Study: NCT03295266
Drug: MK-3866
Normalized name: vitamin MK 7
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single IV infusion of MK-3866 150 mg administered over 30 minutes at Hour 0 on Day 1 of treatment period.
Study: NCT01665599
Drug: Testosterone gel (FE 999303)
Normalized name: Testosterone
DrugBank: (1,2,6,7-3H)Testosterone (DB14093)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT03984838
Drug: JULUCA (Dolutegravir and Rilpivirine) 50mg/25mg FDC tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: JULUCA tablets will be administered orally once daily with a meal. It will be available as a fixed dose combination of Dolutegravir 50mg and Rilpivirine 25mg.
Study: NCT04121039
Drug: POF
Normalized name: Ta-Poff
Approvals — FDA: no, EMA: no, PMDA: no
Description: The POF regimen consisted of a 3-hour infusion of paclitaxel (135 mg/m2) followed by oxaliplatin (85 mg/m2) and Calcium Levofolinate (200 mg/m2).Subsequently, a 46-hour infusion of fluorouracil (2400 mg/m2) was administered using an ambulatory pump, repeating the cycle every 14 days.
Study: NCT03734991
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo
Study: NCT04182880
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo will be administered
Study: NCT04263298
Drug: Capecitabine Oral Product
Normalized name: capecitabine Oral Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Capecitabine 2000mg/m2 twice daily x 14 days followed by 7 days off
Study: NCT02696902
Drug: MEDI3902
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive a single IV dose of MEDI3902 500 mg and 1500 mg in MEDI3902 500 mg arm and MEDI3902 1500 mg arm, respectively.
Study: NCT03421496
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching oral solution
Study: NCT02716038
Drug: MPDL3280A
Approvals — FDA: no, EMA: no, PMDA: no
Description: MPDL3280A is a human, Fc optimized, monoclonal antibody directed against the protein ligand programmed cell death-1 ligand 1 (PD-L1), with potential immune checkpoint inhibitory and antineoplastic activities. Atezolizumab binds to PD-L1, blocking its binding to and activation of its receptor programmed death 1 (PD-1) expressed on activated T-cells, which may enhance the T-cell-mediated immune response to neoplasms and reverse T-cell inactivation. MPDL3280A 1200 mg will be administered as a 60 minute IV infusion on first administration, then over 30 minutes subsequently if tolerated.
Study: NCT04360434
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Formulation buffer of NI006, matching volume of NI006 doses will be administered intravenously
Study: NCT00691678
Drug: Glucosamine
Normalized name: Glucosamine
DrugBank: Glucosamine (DB01296)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 500mg glucosamine TID for twenty-four weeks
Study: NCT01218425
Drug: Levodopa/carbidopa 125 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral dose, 100 mg levodopa, 25 mg carbidopa in one capsule
Study: NCT02872519
Drug: (S)-4-(3-[18F]Fluoropropyl)-L-glutamic acid (18F-FSPG)
Normalized name: 18F-FSPG
DrugBank: Florilglutamic acid F-18 (DB15041)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Given by IV
Study: NCT01684111
Drug: BIBF 1120
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 x 150 mg capsules, oral, daily (Start dose)
Study: NCT02485327
Drug: Technosphere Insulin SAR439065 Afrezza®
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmaceutical form: dry powder~Route of administration: oral inhalation
Study: NCT00033943
Drug: deligoparin
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02807961
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo comparator
Study: NCT01028755
Drug: BAY79-4620
Approvals — FDA: no, EMA: no, PMDA: no
Description: BAY79-4620 will be administered as 1 hour IV infusion. Dose escalation will be dependent on any dose limiting toxicities
Study: NCT02916706
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02826798
Drug: VBI-1501A 0.5 μg
Approvals — FDA: no, EMA: no, PMDA: no
Description: VBI-1501A: 0.5 μg with alum-administered as a 0.5 mL intramuscular injection on Days 0, 56, and 168
Study: NCT02826798
Drug: VBI-1501A 1.0 μg
Approvals — FDA: no, EMA: no, PMDA: no
Description: VBI-1501A: 1.0 μg with alum with alum-administered as a 0.5 mL intramuscular injection on Days 0, 56, and 168
Study: NCT02826798
Drug: VBI-1501A 2.0 μg
Approvals — FDA: no, EMA: no, PMDA: no
Description: VBI-1501A: 2.0 μg with alum-administered as a 0.5 mL intramuscular injection on Days 0, 56, and 168
Study: NCT02826798
Drug: VBI-1501 1.0 μg
Approvals — FDA: no, EMA: no, PMDA: no
Description: VBI-1501: 1.0 μg without alum-administered as a 0.5 mL intramuscular injection on Days 0, 56, and 168
Study: NCT02826798
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: buffer/sucrose used for VBI-1501 suspension- administered as a 0.5 mL intramuscular injection on Days 0, 56, and 168.
Study: NCT01268098
Drug: NPSP558
Approvals — FDA: no, EMA: no, PMDA: no
Description: All patients will inject NPSP558 25 or 50 µg SC QD into alternating thighs in the morning via a multidose injection pen device.
Study: NCT00034853
Drug: meloxicam oral suspension
Normalized name: Meloxicam Oral Suspension
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03888222
Drug: Placebo Oral Tablet
Normalized name: placebo ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fifteen (15) patients in group 1 will receive the matching placebo(sugar pill) one (1) tablet orally once daily for 3 months (90 days) .
Study: NCT03921242
Drug: Sulfonylurea
Normalized name: Sulfonylurea
Approvals — FDA: no, EMA: no, PMDA: no
Description: Newly initiated and regular sulfonylurea dosage as prescribed by each patient's medical care provider
Study: NCT03921242
Drug: GLP1 receptor agonist
Approvals — FDA: no, EMA: no, PMDA: no
Description: Newly initiated and regular GLP1 receptor agonist dosage as prescribed by each patient's medical care provider
Study: NCT02561078
Drug: Human regular U-500 insulin (CSII)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered SC
Study: NCT02561078
Drug: Human regular U-500 insulin (MDI)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered SC
Study: NCT04333732
Drug: MR or M-M-R II ® vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Education and surveillance plus MR or M-M-R II ® vaccine
Study: NCT04333732
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo injection
Study: NCT00148252
Drug: Mycophenolate mofetil withdrawal
Normalized name: Mycophenolate Mofetil
DrugBank: Mycophenolate mofetil (DB00688)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT03376698
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral administration of Placebo once daily for 12 weeks
Study: NCT01828359
Drug: Amosartan® tab
Approvals — FDA: no, EMA: no, PMDA: no
Description: comparison of different combination of anti-hypertension drug
Study: NCT01828359
Drug: Cozaar® plus pro tab
Approvals — FDA: no, EMA: no, PMDA: no
Description: comparison of different combination of anti-hypertension drug
Study: NCT04354246
Drug: Dose escalation: COM902 monotherapy.
Approvals — FDA: no, EMA: no, PMDA: no
Description: COM902 monotherapy administered IV every 3 weeks in sequential dose escalation doses in cohorts of subjects.
Study: NCT04354246
Drug: Cohort expansion: COM902 (RDFE) monotherapy.
Approvals — FDA: no, EMA: no, PMDA: no
Description: COM902 monotherapy (RDFE) in subjects with multiple myeloma. COM902 will be administered IV every 3 weeks.
Study: NCT00119990
Drug: Physioneal (dialysate) 1.36% and 2.27%
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 liter of Physioneal of 1.36% or 3.86% are given with one fill for 4 hours one two different days.
Study: NCT04354246
Drug: Cohort expansion: COM902 in combination with COM701 (both at the RDFE).
Approvals — FDA: no, EMA: no, PMDA: no
Description: COM902 in combination with COM701 (both at RDFE) in subjects with select tumor types who have exhausted standard treatment - HNSCC, CRC (MSS), NSCLC. All study drugs will be administered IV every 3 weeks.
Study: NCT03418493
Drug: LY3316531 - IV
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered IV.
Study: NCT03418493
Drug: Placebo - IV
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered IV.
Study: NCT02418845
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00721812
Drug: GSK1399686
Approvals — FDA: no, EMA: no, PMDA: no
Description: Safety and tolerability dose escalation in normal human volunteers
Study: NCT00874432
Drug: angiotensin converting enzyme inhibitor
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active comparator in chronic kidney disease and age matched control will take 1x40mg per day Placebo comparator in chronic kidney disease and age matched control will take 1 placebo pill per day
Study: NCT00790114
Drug: AZD7325
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral, day 1-12
Study: NCT00790114
Drug: Caffeine
Normalized name: Caffeine
DrugBank: Caffeine (DB00201)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: single dose, twice during treatment
Study: NCT01809041
Drug: remifentanil
Normalized name: Remifentanil
DrugBank: Remifentanil (DB00899)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT03417037
Drug: Chemotherapy
Normalized name: Chemotherapy Glove SML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Platinum-based doublet chemotherapy
Study: NCT03460847
Drug: Steroids
Normalized name: CORTICOSTEROIDS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients with active colitis ulcerosa who need steroids because of their disease course. 1mg/kg bodyweight for one week, followed by a tapping periode.
Study: NCT01284309
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral
Study: NCT00364390
Drug: Anginera, a human tissue replacement therapy
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03305809
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered orally.
Study: NCT03872388
Drug: Capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Patients not eligible to receive atorvastatin in group II will be enrolled into non-statin observation group with/without capecitabine treatment. Capecitabine administration will be dosed as per standard of care. Standard of care dosing of Capecitabine is a 21 day cycle consisting 14 days on and 7 days off. The starting dosing will be per physician discretion, but may be up to 2500mg/m2 per day.
Study: NCT01176318
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo capsule, twice daily for 10 days
Study: NCT04014790
Drug: RGI-2001
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects will receive 6 weekly doses of RGI 2001, 100 μg/kg via IV administration after completion of alloHSCT
Study: NCT04014790
Drug: Standard of Care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard of care prophylaxis regimen will be administered according to institutional guidelines
Study: NCT00816556
Drug: Estriol
Normalized name: Estriol
DrugBank: Estriol (DB04573)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Estriol 10 micrograms added to Vanicream Lite 0.5 grams applied to vaginal introitus daily for 2 weeks and then twice weekly for 10 weeks.
Study: NCT01057251
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg or 20 mg once daily, oral administration
Study: NCT02509312
Drug: Ketorolac
Normalized name: Ketorolac
DrugBank: Ketorolac (DB00465)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patients in the experimental arm will receive ketorolac 30 mg in 1 ml at the time of cord clamp and then for 3 more doses every 6 hours.
Study: NCT02509312
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients in the control arm will receive normal saline 1 ml at the time of cord clamp and then for 3 more doses every 6 hours.
Study: NCT03927690
Drug: LKA651
Approvals — FDA: no, EMA: no, PMDA: no
Description: LKA651 5 mg Intravitreal injection, every 4 weeks for 12 weeks in the treatment phase